What factors drove the changes in Cardiff Oncology's revenue and profit?

What guidance did Cardiff Oncology's management provide for the next earnings period?

What is Cardiff Oncology's latest dividend and current dividend yield?

What were the key takeaways from Cardiff Oncology’s earnings call?

What does Cardiff Oncology do and what are its main business segments?

What were the key takeaways from Cardiff Oncology's earnings call?

What is the revenue and EPS growth rate for Cardiff Oncology year over year?

What is the market's earnings forecast for Cardiff Oncology next quarter?

- **Breakthrough Efficacy**: 64% ORR at 30 mg dose vs 33% control, with superior tumor regression depth in lead arm.
- **Fast-Track Enrollment**: 90-patient trial set to complete enrollment in Q1 2025, with key data readout in H1.
- **Strong Financial Buffer**: $91.7M cash runway to Q1 2027, no immediate funding needs.
- **Strategic IP Protection**: 2043-expiring patent secures onvansertib + bev combo exclusivity in KRAS-mutated mCRC.
- **Breast Cancer Expansion**: Preclinical success with ENHERTU combo opens new oncology front.

**【CEO Key Updates】**
- **CRDF-004 Trial Data Highlights**: 30 mg dose of onvansertib achieved a 64% ORR vs 33% in control arm, with 5 of the deepest tumor regressions observed in the 30 mg arm. The safety profile remains favorable, with no dose-limiting toxicities across 380+ patients.
- **Enrollment Completion**: Trial enrollment for 90 evaluable patients is expected to conclude in the next few weeks, with plans for a substantive data update in H1 2025.
- **FDA Registrational Strategy**: Pfizer's BREAKWATER trial precedent supports using ORR as an accelerated approval endpoint, aligning with Cardiff's Phase 2 design for onvansertib in RAS-mutated mCRC.
- **Intellectual Property Expansion**: New patent issued for onvansertib + bevacizumab in KRAS-mutated mCRC, expiring in 2043, reinforcing exclusivity for lead indication.
- **Breast Cancer Pipeline Progress**: Preclinical data shows onvansertib synergizes with paclitaxel and ENHERTU in HR+ breast cancer models resistant to first-line therapies.

**【CFO Financial Overview】**
- **Cash Position**: $91.7M as of Q4 2024, including $40M from December capital raise, providing runway into Q1 2027.
- **Operational Efficiency**: Q4 cash burn of $10.3M, consistent with historical trends. No immediate need for additional funding beyond existing plans.
- **Capital Markets Activity**: Filed new S-3 shelf registration to maintain flexibility for future financings, with no shares issued in the process.

**【Q&A Key Takeaways】**
- **Data Timing & Maturity**: Next update will include a mature efficacy dataset, with PFS analysis expected beyond H1 2025.
- **Dose Selection & FDA Dialogue**: FDA meeting to discuss 30 mg vs 20 mg dose and final registrational trial design anticipated after interim data review.
- **Competitive Landscape**: KRAS G12C inhibitors (e.g., Amgen's drug) target <4% of RAS-mutated mCRC patients and are limited to second-line use, posing minimal threat to onvansertib's first-line positioning.
- **Accelerated Approval Pathway**: Pfizer's BREAKWATER trial used 110 patients per arm for interim ORR analysis, aligning with Cardiff's trial size and endpoint strategy.

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Cardiff Oncology (CRDF)-8 Aug 24-2024 Q2 Earnings call transcript

Cardiff Oncology (CRDF)-2 May 24-2024 Q1 Earnings call transcript

Cardiff Oncology (CRDF)-29 Feb 24-2023 Q4 Earnings call transcript

Actual									-0.41	-0.51	-0.19	-0.19	-0.14	-0.17	-0.17	-0.23	-0.25	-0.24	-0.2	-0.2	-0.25	-0.25	-0.22	-0.21	-0.22	-0.26	-0.25	-0.22	-0.2	-0.21	-0.17
Forecast										-0.24	-0.1867	-0.14	-0.1475	-0.15	-0.17	-0.1717	-0.2333	-0.246	-0.264	-0.235	-0.226	-0.2608	-0.284	-0.2671	-0.2485	-0.2475	-0.2695	-0.2464	-0.1851	-0.1925	-0.205
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-112.50%	-1.77%	-35.71%	+5.08%	-13.33%	0.00%	-33.95%	-7.16%	+2.44%	+24.24%	+14.89%	-10.62%	+4.14%	+22.54%	+21.38%	+11.47%	-5.05%	+7.24%	+10.71%	-8.05%	-9.09%	+17.07%

CRDF

CRDF fundamentals

CRDF Q3 2025 Earnings

Earnings Call

You can ask Aime

CRDF

CRDF fundamentals

CRDF Q3 2025 Earnings

Earnings Call

CRDF Earnings Call Summary for Q3/2025 Apr 3, 2026

CRDF Earnings Call Summary for Q2/2025 Apr 3, 2026

CRDF Earnings Call Summary for Q1/20254:30 PM on May 1, 2025

CRDF Earnings Call Summary for Q4/20244:30 PM on Feb 27, 2025

CRDF Earnings Call Summary for Q3/2024 Apr 3, 2026

You can ask Aime